- Patent Title: Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
-
Application No.: US16317665Application Date: 2017-07-14
-
Publication No.: US10711029B2Publication Date: 2020-07-14
- Inventor: Jean-Pierre Sommadossi , Adel Moussa
- Applicant: Atea Pharmaceuticals, Inc.
- Applicant Address: US MA Boston
- Assignee: ATEA Pharmaceuticals, Inc.
- Current Assignee: ATEA Pharmaceuticals, Inc.
- Current Assignee Address: US MA Boston
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- International Application: PCT/US2017/042159 WO 20170714
- International Announcement: WO2018/013937 WO 20180118
- Main IPC: C07H19/20
- IPC: C07H19/20 ; A61P31/14
Abstract:
Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.
Public/Granted literature
Information query
IPC分类:
